Business Context and Reporting Period
Company: Cryomedical Sciences, Inc. (Ticker: CRYM)
Reporting Period: Thirteen and twenty-six weeks ended June 25, 2000 (Form 10-QSB).
Business Overview: The Company researches, develops, manufactures, and markets cryosurgical systems for low-temperature medicine, including the AccuProbe and Blizzard series. In June 2000, the Company effected a 1-for-5 reverse stock split.
Key Financial Metrics
| Metric | 26 Weeks Ended June 25, 2000 | 26 Weeks Ended June 27, 1999 |
|---|---|---|
| Revenues | $633,063 | $841,124 |
| Gross Profit | $365,483 (58% margin) | $296,977 (35% margin) |
| Net Loss | $(1,007,736) | $(397,355) |
| Net Loss Per Share | $(0.13) | $(0.06) |
| Cash and Equivalents (End of Period) | $5,285,508 | $3,275 |
| Working Capital | $4,561,804 | $(33,207) |
| Short-term Debt | $1,020,000 | $120,000 |
Cash Flow: Net cash used in operating activities was $(1,086,745). Net cash provided by financing activities was $6,400,493, driven primarily by a private placement.
Material Changes vs. Prior Period
- Revenue Decline: Revenues decreased 25% year-over-year for the 26-week period, attributed to a decline in the number of CMS AccuProbe systems and accessories sold.
- Margin Expansion: Gross profit margin improved to 58% from 35% in the prior year due to changes in product/service mix and reduced overhead from staff reductions and relocation.
- Expense Surge:
- R&D: Increased 416% to $636,780 due to raw material usage and development of the AccuProbe 800 series.
- G&A: Increased 66% to $681,234 due to relocation costs to Ewing, NJ, and higher legal/consulting fees.
- Sales & Marketing: Decreased 37% to $91,185 due to reduced commissions and personnel.
- Liquidity Transformation: Cash balances increased from $7,952 to $5.29 million following a May 2000 private placement raising $5.7 million.
Outlook, Risks, and Contingencies
Guidance and Outlook: Management believes sales for the remainder of fiscal 2000 may exceed prior year levels due to favorable HCFA reimbursement policies for prostate cryosurgery. Success depends on implementing manufacturing protocols and increasing marketing efforts. Capital expenditures for equipment are expected to remain under $1.5 million for the year.
Legal Proceedings: On April 6, 2000, Endocare, Inc. sued the Company alleging patent infringement (U.S. Patent No. 5,647,868) regarding cryosurgical control systems. Endocare seeks an injunction and damages. The Company has denied allegations and counterclaimed for invalidity and unenforceability of the patent.
Risks: Forward-looking statements are subject to risks including market acceptance, regulatory conditions, and the outcome of pending litigation. The Company relies on the ability to continue operations without additional financing beyond current resources.
Investor Verification Checklist
- Capital Raise Details: Verify the terms of the May 2000 private placement ($5.7M raised via 2,234,000 units at $2.55/unit) and the associated warrant exercise price ($1.25).
- Patent Litigation Status: Monitor the progress of the Endocare, Inc. infringement suit and potential impact on product sales or injunctions.
- Revenue Sustainability: Assess whether the 25% revenue decline is a temporary anomaly or a structural shift in demand for AccuProbe systems.
- Burn Rate vs. Cash: Evaluate if the $5.3M cash balance is sufficient to cover the current operating loss rate (~$1M per 26 weeks) and R&D spend without further dilution.
- Reimbursement Policy: Confirm the implementation and market impact of the new HCFA coverage policy for prostate cryosurgery.